Visus Therapeutics to Attend TD Cowen’s 43rd Annual Health Care Conference

Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for the front and back of the eye, today announced that Ben Bergo, Co-Founder and Chief Executive Officer, TD Cowen, 43 Will participate in th Annual Healthcare Conference. March 6-8, 2023 in Boston.

Mr. Burgo will also be available for one-on-one meetings with investors on March 8, 2023. Click here to schedule a meeting during the conference.

About Visus Therapeutics
With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage biopharmaceutical company focused on developing multitargeted ophthalmic therapies for the anterior and posterior segments of the eye. The company is developing novel, pupil-modulating treatments designed to correct near vision loss associated with presbyopia. In parallel, Visus Therapeutics is advancing its pipeline of early-stage ophthalmic drug candidates designed to preserve and restore visual function including cataracts and presbyopia, ocular surface and corneal disease, glaucoma , and are associated with leading causes of vision loss, including age-related macular degeneration. .

Leave a Comment